TeleDaaS
TeleDaaS is a U.S.-based medical practice (TeleDaaS PLLC) that delivers cloud-based, physician-approved personalized dosimetry planning for Y90 radioembolization cancer treatments, serving hospitals, health systems, CROs, and pharmaceutical manufacturers on a professional-services basis.
- Company typePrivate
- Founded2021
- HeadquartersEvanston, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
What TeleDaaS does
TeleDaaS is a U.S.-based medical practice (TeleDaaS PLLC, Illinois) that delivers cloud-based, physician-approved personalized dosimetry plans for Y90 radioembolization cancer treatments, primarily targeting hospitals, health systems, and physician practices treating liver cancer. The service is positioned around the clinical finding that personalized dosimetry substantially improves patient outcomes—referenced DOSISPHERE-1 trial data shows 2.3x improvement in median survival and an 8-fold increase in eligibility for curative surgery versus standard dosimetry—while also capturing full reimbursement under existing CPT codes by ensuring complete, billable documentation (the company states 99% of sites may be underbilling without proper dosimetry documentation). The product reduces physician time by 1-2 hours per case, is delivered entirely via cloud with no on-premise IT installation, and integrates with existing hospital imaging workflows.
The core technology is a dosimetry-as-a-service platform licensed from Mirada Medical Ltd., whose software carries ISO 13485 and ISO 27001 certifications and has been used across multiple clinical trials. TeleDaaS operates two service lines: "For The Clinical Practice" (treatment planning for hospitals treating Y90 patients) and "DoseLab" (research/clinical-trial dosimetry for CROs and pharmaceutical manufacturers developing radiopharmaceuticals). The team is small (1-10 employees) and is led by Co-Founder/CEO Dr. Shamar Young (Chief of Interventional Radiology at the University of Arizona), Co-Founder/COO Shelby Schweitzer, and CMO Dr. Mark Crockett, supported by PhD-level scientific advisors with over 90 years of combined experience in medical imaging, physics, and clinical translation.
TeleDaaS makes money by selling dosimetry treatment planning as a professional service to enterprise healthcare buyers on a consultative, quote-based model with a pilot program for early adopters. Its go-to-market is sales-led and direct, targeting U.S. hospitals, health systems, CROs, and pharmaceutical manufacturers, with thought-leadership content, an active LinkedIn presence, and healthcare-industry earned media supporting demand generation. The company is privately held, has not disclosed any external funding rounds, and currently operates only within the United States.
TeleDaaS firmographics
Firmographics- Name
- TeleDaaS
- Legal name
- TeleDaaS PLLC
- Website
- https://teledaas.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- TeleDaaS is a U.S.-based medical practice (TeleDaaS PLLC) that delivers cloud-based, physician-approved personalized dosimetry planning for Y90 radioembolization cancer treatments, serving hospitals, health systems, CROs, and pharmaceutical manufacturers on a professional-services basis.
- Ownership category
- akta.pro rank
TeleDaaS industry classification
Industry- Product category
- Radiation Oncology Dosimetry Services
- NAICS
- Diagnostic Imaging Centers (621512)
- SIC
- Services-Health Services (8000), Services-Offices & Clinics Of Doctors Of Medicine (8011)
- akta.pro primary industry
- Oncology Telemedicine Platforms (HLALAGAH)
Keywords
Where TeleDaaS is headquartered
LocationHeadquarters
- HQ city
- Evanston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
TeleDaaS business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Others
Revenue model
- Dosimetry Treatment Planning Services: TeleDaaS provides dosimetry services to hospitals and health systems for Y90 cancer treatment planning. The service helps hospitals improve revenue capture under existing CPT codes by ensuring complete, billable documentation. Services are delivered via cloud-based platform with physician oversight.
- Clinical Trial Dosimetry Services: Provides dosimetry services to clinical research organizations (CROs) and pharmaceutical manufacturers for clinical trials involving Y90 therapies. Supports drug development and clinical translation.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
TeleDaaS product offering
Product offeringCore offering
TeleDaaS provides physician-approved personalized dosimetry plans for Y90 radioembolization cancer treatments to hospitals, healthcare practices, and clinical research organizations. The service is delivered through a cloud-based dosimetry-as-a-service platform (licensed from Mirada Medical) that integrates with existing hospital imaging workflows and reduces physician planning time by 1-2 hours per case. The company operates two service lines: clinical practice dosimetry (For The Clinical Practice) for hospitals treating liver cancer patients and research/clinical trial dosimetry (DoseLab) for pharmaceutical manufacturers and CROs.
Product overview
TeleDaaS operates as a Dosimetry-as-a-Service platform offering two integrated service lines: For The Clinical Practice provides personalized dosimetry planning for hospitals treating liver cancer with Y90 radioembolization, while For Research/Clinical Trials (DoseLab) supports pharmaceutical manufacturers and CROs conducting radiopharmaceutical clinical trials. Both services leverage a cloud-based technology platform licensed from Mirada Medical and are delivered by a team of licensed physicians, technologists, and PhD-level scientists.
Differentiator
Problem solved
Functional benefit
Products and services
- Dosimetry-as-a-Service (Y90 Treatment Planning) Cloud-based personalized dosimetry service providing physician-approved treatment plans for Y90 radioembolization cancer treatments, reducing physician planning time by 1-2 hours per case. Targeted at hospitals and healthcare practices treating liver cancer patients with Y90.
- For The Clinical Practice (Clinical Dosimetry Service) Dosimetry service tailored for hospitals and clinical practices treating cancer patients with Y90 radioembolization, offering streamlined workflows and comprehensive billing documentation to support full CPT-code reimbursement.
- DoseLab (For Research / Clinical Trials) Dosimetry service supporting clinical trials for radiopharmaceutical development, serving pharmaceutical manufacturers and CROs conducting trials involving Y90 therapies. Delivers clinical-grade precision dosimetry analysis to support drug development, validation, and trial compliance.
Quantifiable outcome
- 2.3x increase in median post-treatment survival (10.7 months to 24.8 months)
- +3 more outcomes
Companies that use TeleDaaS
Customer profileSegments2 records
Ideal customer profiles2 records
TeleDaaS technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
TeleDaaS partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Mirada Medical Ltd.coreMirada Medical provides management, administrative, and technology services to TeleDaaS PLLC. The company licenses its cloud-based dosimetry technology platform to TeleDaaS. Mirada Medical maintains ISO 13485 and ISO 27001 compliance which TeleDaaS leverages through its service agreement. Mirada's advanced dosimetry technology has been used in multiple clinical trials including DOSISPHERE-1.
Scale indicators5 records
Recent moves5 records
Expansion highlights5 records
TeleDaaS competitors and assessment
Company assessmentDirect peers
- Mirada Medical: Licensor of TeleDaaS' core cloud dosimetry platform and a provider of advanced dosimetry software used in Y90 and other radiopharmaceutical trials. Directly comparable because it operates in the same dosimetry software space and even shares staff/administrative services with TeleDaaS.
Emerging players
- MIM Software: Provider of medical imaging analysis software, including solutions used in radiation therapy and radiopharmaceutical dosimetry workflows. Comparable because it offers software tools that hospitals could use in place of TeleDaaS' outsourced dosimetry service.
- RaySearch Laboratories: Developer of treatment planning systems (RayStation) used in radiation therapy and emerging radiopharmaceutical workflows. Comparable because it competes for the same hospital treatment planning budget and increasingly supports Y90-style dosimetry.
- Brainlab: Provider of software-driven treatment planning and image-guided intervention tools used in radiation oncology and interventional radiology. Comparable because it offers planning software that competes for the same hospital IT budget that funds TeleDaaS engagements.
Broad incumbents
- Accuray: Developer of radiation therapy systems (CyberKnife, TomoTherapy) with associated treatment planning software. Comparable as a broader radiation oncology incumbent whose planning tools overlap with dosimetry workflows.
- Varian Medical Systems (Siemens Healthineers): Global leader in radiation oncology treatment planning software and systems. Comparable because it provides enterprise treatment planning platforms that overlap with the dosimetry planning step TeleDaaS performs for Y90.
- Sirtex Medical: Manufacturer of SIR-Spheres Y90 resin microspheres, the main alternative to TheraSphere. Comparable because it competes in the Y90 radioembolization market that drives demand for TeleDaaS' dosimetry planning service.
- Elekta: Global provider of radiation therapy and radiosurgery hardware and software. Comparable because it sells into the same hospital radiation oncology departments that purchase TeleDaaS' dosimetry service.
- Boston Scientific (TheraSphere): Manufacturer of TheraSphere Y90 radioembolization microspheres and the sponsor of the DOSISPHERE-1 trial. Comparable because it sits in the same Y90 treatment workflow and benefits from broader adoption of personalized dosimetry that TeleDaaS provides.
- Philips Radiation Oncology: Offers imaging, simulation, and treatment planning solutions across radiology and oncology. Comparable because large hospital systems may consolidate dosimetry workflows onto Philips platforms instead of using a specialist like TeleDaaS.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
TeleDaaS social profiles
Digital presenceTeleDaaS compliance and trust
Trust signalCompliance3 records
TeleDaaS financial estimates
Financial estimateRevenue estimate
Valuation estimate
TeleDaaS leadership team
Management profileNumber of profiles
Profiles4 records
TeleDaaS funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
TeleDaaS M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about TeleDaaS
What does TeleDaaS do?
TeleDaaS provides physician-approved personalized dosimetry plans for Y90 radioembolization cancer treatments to hospitals, healthcare practices, and clinical research organizations. The service is delivered through a cloud-based dosimetry-as-a-service platform (licensed from Mirada Medical) that integrates with existing hospital imaging workflows and reduces physician planning time by 1-2 hours per case. The company operates two service lines: clinical practice dosimetry (For The Clinical Practice) for hospitals treating liver cancer patients and research/clinical trial dosimetry (DoseLab) for pharmaceutical manufacturers and CROs.
Is TeleDaaS a public or private company?
TeleDaaS is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was TeleDaaS founded?
TeleDaaS was founded in 2021. It employs 1 to 10 people.
Where is TeleDaaS based?
TeleDaaS is headquartered in Evanston, United States, in the North America region.
How does TeleDaaS make money?
Two revenue lines are on record. Dosimetry Treatment Planning Services are the primary driver. The others are clinical Trial Dosimetry Services.
Who are TeleDaaS's main competitors?
Mirada Medical is listed as a direct peer. Emerging players are MIM Software, RaySearch Laboratories and Brainlab. Broad incumbents are Accuray, Varian Medical Systems (Siemens Healthineers), Sirtex Medical, Elekta, Boston Scientific (TheraSphere) and Philips Radiation Oncology.
Does TeleDaaS have an API?
No public API is recorded for TeleDaaS.
What industry is TeleDaaS in?
TeleDaaS's product category is Radiation Oncology Dosimetry Services. Its primary akta.pro industry code is HLALAGAH, Oncology Telemedicine Platforms. Its NAICS code is 621512 and its SIC code is 8000.